REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms > Additional Hetero Ring Containing > Ring Nitrogen In The Additional Hetero Ring (e.g., Oxazole, Etc.) Ring Nitrogen In The Additional Hetero Ring (e.g., Oxazole, Etc.)Ring Nitrogen In The Additional Hetero Ring (e.g., Oxazole, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/18/07 - 20070015798 - Efficient and stereoselective process for large scale synthesis of (3r)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives This invention relates to an efficient process for large scale stereoselective production of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-ones and key intermediates used for the preparation of benzofuranyl pyrroloquinolones as potent and selective PDE5 inhibitors for the treatment of erectile dysfunction, as well as pharmaceutical compositions and methods of treatment utilizing these compounds. ... 01/18/07 - 20070015797 - Substituted acid derivatives useful as antidiabetic and antiobesity agents and method wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R1, R2, R2a, R2b, R2c, R3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents. ... 01/18/07 - 20070015796 - Compositions and methods for treatment of fibrosis Methods for the treatment of fibrosis, including liver fibrosis, via administration of FXR agonists are provided. ... 01/04/07 - 20070004780 - Treatment of diabetes with thiazolidinedione and metformin A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a biguanide antihyperglycaemic agent, to a mammal in need thereof and a ... 11/09/06 - 20060252803 - Hydrogenation of precursors to thiazolidinedione antihyperglycemics Provided is pioglitazone having a low level of impurities, especially a low level of the precursor PIE. Also provided is a method for making pioglitazone having a low level of impurities. ... 11/09/06 - 20060252802 - Small molecule cyclin d1 ablative agents Cyclin D1 ablative agents and methods of using these agents in the treatment of cancers, and particularly breast cancer. Also provided are methods of treating cancer, the method comprising administering a therapeutically effective amount of one of the cyclin D1 ablative agents described herein to a subject in need of ... 11/09/06 - 20060252801 - Small molecule bcl-xl/bcl-2 binding inhibitors Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject ... 11/02/06 - 20060247279 - Thiazolidinedione derivative and its use as antidiabetic A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm−1; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm−1; and/or (iii) a solid-state nuclear magnetic resonance ... 10/26/06 - 20060241151 - Pyrid-2-one derivatives and methods of use Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The ... 08/31/06 - 20060194844 - 2-acylaminothiazole derivative or salt thereof 2-Acylaminothiazole derivatives or salts thereof which have a platelet increasing activity based on an excellent human c-mpl-Ba/F3 cell growth function and a function of accelerating formation of megakaryocytic colonies and which are useful for treating thrombocytopenia are provided. ... 08/24/06 - 20060189660 - 5-(4-(2-n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl thiazolidine - 2,4-dione and pharmaceutical compositions comprising the same A compound, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (‘Compound (I)’), or a pharmaceutically acceptable form thereof, in particulate form wherein the median value of the volume mean diameter of the particles is within the range 500 nm to 5 micrometres and medicinal uses thereof. ... 08/24/06 - 20060189659 - Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione maleic acid salt (ii) provides an infra red spectrum containing peaks at 764 and 579 cm−1; and/or (iii) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in Figure II; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such ... 08/03/06 - 20060173047 - Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1, 3-oxazolines and their use as anticoagulant and antithrombotics The invention relates to the field of blood coagulation, more particularly, to novel compounds of general formula (I), to a method for producing said compounds and to their use as active ingredients in medicaments for the prevention and/or the treatment of diseases. ... 08/03/06 - 20060173046 - Hydroxypyridine cgrp receptor antagonists The present invention is directed to compounds of Formula I: I (where variables R1, R2, R3 and R4 are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as headache, migraine and cluster headache. The ... 07/27/06 - 20060167063 - Process for the manufacture of isradipine The present invention relates to an improved method for the manufacture of Isradipine, 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester. which, involves reacting 2,1,3-benzoxadiazole-4-carboxaldehyde with methyl acetoacetate in the presence of acetic acid and piperidine in diisopropyl ether. To obtain the product 2-acetyl-3-benzofurazan-4-yl-acrylic acid methyl ester which is then reacted with isopropyl-β-aminocrotonate ... 07/27/06 - 20060167062 - Enema preparation wherein R1 represents a phenyl group which may have 1 to 3 lower alkoxy groups as substituents on the phenyl ring and R2 a pyridyl group which may have 1 to 3 carboxyl groups as substituents on the pyridine ring. ... 07/27/06 - 20060167061 - Novel process to prepare pioglitazone via several novel intermediates A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine. ... 07/27/06 - 20060167060 - Pyrazole and pyrrole carboxamide insecticides This invention provides compounds of Formula (I), N-oxides and salts thereof wherein: A is O or S; B is a phenyl ring or a pyridine ring, each ring optionally substituted with 1 to 5 R; J is a pyrazole or a pyrrole heterocyclic ring system as defined herein; and; R1 ... 06/22/06 - 20060135566 - 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof wherein R1 represents hydrogen, hydrocarbon, heterocycle, amino, acyl, R2 represents an aromatic group, R3 represents hydrogen, pyridyl, aromatic hydrocarbon, X represents oxygen, optionally oxidized sulfur, Y represents a bond, an oxygen, optionally oxidized sulfur, a group represented by the formula NR4 (R4 represents hydrogen, hydrocarbon or acyl) and Z represents ... 06/15/06 - 20060128759 - Substituted isoxazole derivatives and their use in pharmaceutics The invention relates to substituted isoxazole derivatives of formula (I), wherein the radicals R1, R2 and R3 have the meanings as cited in the description. The inventive compounds comprise an immunomodulatory action and/or an action that inhibits the release of cytokines and are thus suited for treating diseases associated with ... 05/11/06 - 20060100247 - Treatment of diabetes with thiazolidinedione and metformin A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a biguanide antihyperglycaemic agent, to a mammal in need thereof and a ... 04/27/06 - 20060089388 - Use of parathyroid hormone-related protein (pthrp) in the diagnosis and treatment of chronic lung disease and other pathologies This invention pertains to the discovery that Parathyroid Hormone-related Protein (PTHrP) can be detect and/or stage, and/or treat chronic lung diseases. In particular, it was discovered that PTHrP levels in broncho-alveolar lavage are indicative of lung “health” and “disease, and can be used to predict lung disease in patients at ... 04/27/06 - 20060089387 - Stabilized pharmaceutical composition comprising antidiabetic agent This invention discloses a stabilized pharmaceutical composition comprising an antidiabetic agent and a stabilizer. The preferred stabilizers are selected from the group consisting of ascorbic acid, malic acid, maleic acid, tartaric acid, furmaric acid, citric acid, or combinations thereof. The antidiabetic agent is selected from the group consisting of [(±)5-[[2-(5-ethyl-2-pyridinyl)ethoxyl]phenyl]methyl]-thiazolidine-2,4-dione ... 03/16/06 - 20060058357 - Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke wherein R2 is 4-pyridyl or 3-pyridyl, R3 is hydrogen, methyl or ethyl and R1 is 3,4- or 3,5-dichloro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p-methyl, p-methoxy or hydrogen. ... 03/09/06 - 20060052420 - Thiazolo-naphthyl acids and methods of using them to modulate PAI-1 expression and to treat PAI-1 related disorders. ... 03/09/06 - 20060052419 - Use of pyridly amides as inhibitors of angiogenesis The invention relates to the use of derivatives of Formula I in the manufacture of a pharmaceutical composition for the treatment of a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred, and to the prevention thereof. (I) ... 02/23/06 - 20060040993 - 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salt Disclosed are 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salts, or solvates thereof; processes for preparing such compounds, compositions comprising such compounds and the use of such compounds in medicine. ... 02/23/06 - 20060040992 - Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines There are provided novel compounds of formula (I) wherein T, X, Y and W are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric ... 02/09/06 - 20060030597 - Method of inhibiting angiogenesis Angiogenesis is inhibited and the growth of tumors is treated by administering an effective amount of a PPAR gamma ligand/agonist, optionally with an RXR receptor ligand. ... 02/02/06 - 20060025453 - Isothiazole dioxides as cxc- and cc-chemokine receptor ligands and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and ... 01/19/06 - 20060014800 - Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders The present invention is directed to compounds having the structure wherein R1, R2, R3, R4, R5 and m are as defined herein. The compounds of this invention are novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders in mammalian subjects. These compounds are also useful modulators ... 01/12/06 - 20060009494 - Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes Acne-affected skin has been found to be accompanied by the presence of matrix-degrading enzymes such as MMPs and neutrophil elastase, induction of neutrophils, and a reduction in procollagen biosynthesis. This invention treats scarring and inflammation accompanying acne by administering, topically or systemically, at least one of (i) an inhibitor of ... 01/05/06 - 20060004059 - Substituted heterocycles for the treatment of diabetes and other diseases The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, ... 01/05/06 - 20060004058 - Sodium salts of 5-'4-'2-(n-methyl-n-(2-pyridyl) amino) ethoxy!benzyl!thiazolidine -2, 4-dione A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt, or a pharmaceutically acceptable solvate thereof, characterised in that the sodium salt is non-hygroscopic or slightly hygroscapic; a pharmaceutical composition containing such a compound and the use of such a compound in medicine. ... 12/29/05 - 20050288336 - Cysteine protease inhibitors The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. ... 12/22/05 - 20050282867 - Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazo-lidine-2,4-dione A novel pharmaceutical compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride, a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine. ... 12/08/05 - 20050272778 - Inhibitors of proteins that bind phosphorylated molecules The present invention provides compounds that can modulate the activity of a target protein, such as a phosphatase, that selectively binds phosphorylated peptides or proteins. The present compounds can be useful in treating diseases or disorders, including, for example, diabetes and obesity, that are connected directly or indirectly to the ... 12/01/05 - 20050267163 - Vanilloid receptor ligands and their use in treatments and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic ... 12/01/05 - 20050267162 - Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione A substantially non-hydrated and non-hygroscopic or slightly hygroscopic hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; a pharmaceutical composition containing such a compound, a process of preparing such a compound and the use of such a compound in medicine. ... 12/01/05 - 20050267161 - Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity wherein the symbols have the meanings given in the specification. ... 11/03/05 - 20050245579 - Iron binding agents Composition, article of manufacture for and method of treating malaria in a human having an infestation of Plasmodium protozoans are described. The method comprises administering a therapeutically-effective amount of a compound of formula (I) or (IV), i.e. sufficient quantity to reduce the population of Plasmodium. The composition of the invention ... 09/29/05 - 20050215596 - Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals Provided herein are cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals ... 09/15/05 - 20050203147 - Biaryl heterocyclic compounds and methods of making and using the same The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at least one heterocylic moiety that are useful as such agents. ... 08/25/05 - 20050187258 - Hydrogenation of precursors to thiazolidinedione antihyperglycemics Provided is pioglitazone having a low level of impurities, especially a low level of the precursor PIE. Also provided is a method for making pioglitazone having a low level of impurities. ... 08/18/05 - 20050182105 - Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function wherein R3a and R4a, and R2b are the same or different and are independently selected from alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, or heteroaryl and substituted heteroaryl; or a pharmaceutically acceptable salt thereof and a prodrug ester thereof. ... 08/18/05 - 20050182104 - Acylaminothiazole derivatives, preparation and therapeutic use thereof Wherein R1, R2, R′2, R3, R4 and R5 are as described herein. The compounds of the present invention exhibit an inhibitory effect on the production of β-amyloid peptide (β-A4) by inhibition of gamma protease. Therefore, the compounds of the present invention are useful in the treatment of pathologies such as ... 08/18/05 - 20050182103 - Substituted 2,3-diphenyl pyridines Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, ... 08/11/05 - 20050176776 - Mitotic kinesin inhibitors The present invention relates to substituted thiazole derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin and MCAK activity, and for inhibiting KSP kinesin and MCAK. The invention also relates to compositions which comprise these compounds, and methods of using them to treat ... 08/11/05 - 20050176775 - Substituted pyridinones and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using ... 08/04/05 - 20050171163 - Mcp-1 receptor antagonists and methods of use thereof The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists. ... 07/28/05 - 20050165062 - Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases. ... 07/14/05 - 20050154027 - Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed. ... 06/30/05 - 20050143424 - Prophylactic and therapeutic agent of diabetes mellitus The invention provides a prophylactic and therapeutic agent of diabetes mellitus, including a combination of an inhibitor of renal glucose reabsorption and a hypoglycemic agent. In accordance with the invention, hyperglycemia after meals, between meals and during fasting can be ameliorated. More specifically, in accordance with the invention, a therapeutic ... 06/16/05 - 20050131027 - Fine particle size pioglitazone The present invention provides pioglitazone of defined particle size distribution. The Pioglitazone of defined particle size can be formulated into a wide variety of dosage forms. ... 06/09/05 - 20050124663 - Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases ... 06/02/05 - 20050119314 - Pharmaceutical composition comprising an acat inhibitor and an insulin resistance reducing agent The present invention provides a pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent as effective components for the prevention or therapy against atherosclerosis or diseases caused by atherosclerosis. ... ### FreshPatents.com Support |